January 2025 – The Journal of Pharmacology & Experimental Therapeutics

Clinical development of the GluN2B-selective NMDA receptor inhibitor NP10679 for the treatment of neurologic deficit after subarachnoid hemorrhage

July 2023 – Clinical Pharmacology in Drug Development

Phase 1 Clinical Results for NP10679, a pH-sensitive GluN2B-selective N-methyl-d-aspartate Receptor Inhibitor

September 2021 – The Journal of Pharmacology & Experimental Therapeutics

A GluN2B-selective inhibitor of NMDA receptor function with enhanced potency at acidic pH and oral bioavailability for clinical use

March 2015 – Neuron

Context-Dependent GluN2B-Selective Inhibitors of NMDA Receptor Function Are Neuroprotective with Minimal Side Effects

February 2014 – Neurocritical Care

pH-Sensitive NMDA Inhibitors Improve Outcome in a Murine Model of SAH